Change search
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • harvard1
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf
Psychological burden in the era of Haart: Impact of selenium therapy
Dept. of Psychiat./Behav. Sci. (D21), Division of Disease Prevention, Miami, United States.
Dept. of Psychiat./Behav. Sci. (D21), Division of Disease Prevention, Miami, United States.
Dept. of Psychiat./Behav. Sci. (D21), Division of Disease Prevention, Miami, United States.
Dept. of Psychiat./Behav. Sci. (D21), Division of Disease Prevention, Miami, United States.
Show others and affiliations
2003 (English)In: International Journal of Psychiatry in Medicine, ISSN 0091-2174, E-ISSN 1541-3527, Vol. 33, no 1, 55-69 p.Article in journal (Refereed) Published
Abstract [en]

Objective: To determine the impact of nutritional (selenium) chemoprevention on levels of psychological burden (anxiety, depression, and mood state) in HIV/AIDS. Method: A randomized, double-blind, placebo-controlled selenium therapy (200 mug/day) trial was conducted in HIV+ drug users from 1998-2000. Psychosocial measures (STAI-State and Trait anxiety, BDI-depression, and POMS- mood state), clinical status (CD4 cell count, viral load), and plasma selenium levels were determined at baseline and compared with measurements obtained at the 12-month evaluation in 63 participants (32 men, 31 women). Results: The majority of the study participants reported elevated levels of both State (68%) and Trait (70%) anxiety. Approximately 25% reported overall mood distress (POMS > 60) and moderate depression (BDI > 20). Psychological burden was not influenced by current drug use, antiretroviral treatment, or viral load. At the 12-month evaluation, participants who received selenium reported increased vigor (p = 0.004) and had less anxiety (State, p = 0.05 and Trait, p = 0.02), compared to the placebo-treated individuals. No apparent selenium-related affect on depression or distress was observed. The risk for state anxiety was almost four times higher, and nearly nine times greater for trait anxiety in the placebo-treated group, controlling for antiretroviral therapy, CD4 cell decline (> 50 cells) and years of education. Conclusions: Selenium therapy may be a beneficial treatment to decrease anxiety in HIV+ drug users who exhibit a high prevalence of psychological burden.

Place, publisher, year, edition, pages
2003. Vol. 33, no 1, 55-69 p.
Keyword [en]
anxiety, HIV infection, selenium
National Category
Psychiatry
Identifiers
URN: urn:nbn:se:hj:diva-27956DOI: 10.2190/PFFD-D920-V041-N5KDISI: 000184567500004PubMedID: 12906343Scopus ID: 2-s2.0-0041767587OAI: oai:DiVA.org:hj-27956DiVA: diva2:854405
Available from: 2015-09-16 Created: 2015-09-16 Last updated: 2015-09-16Bibliographically approved

Open Access in DiVA

No full text

Other links

Publisher's full textPubMedScopus

Search in DiVA

By author/editor
Lecusay, Robert
In the same journal
International Journal of Psychiatry in Medicine
Psychiatry

Search outside of DiVA

GoogleGoogle Scholar

Altmetric score

Total: 124 hits
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • harvard1
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf